Deborah Wong

10PUBLICATIONS
105CO-AUTHORS
Predictive and prognostic markersCancer diagnosisAllergyMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Aug 19, 2026
Danvatirsen plus pembrolizumab versus pembrolizumab for recurrent and/or metastatic head and neck squamous cell carcinoma (PEMDA-HN): a randomized, phase 2 trial.

|May 08, 2026
Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial.

|Dec 04, 2025
Evolving Use of Circulating Tumor DNA for HPV+ Oropharyngeal Carcinoma: Consensus Recommendations From the California Head and Neck Consortium.

Allen S Ho, Justin T Moyers, Shirin Attarian

|Jun 11, 2025
Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas.

Kevin J Harrington, Stephane Champiat, Joshua D Brody

|Sep 14, 2024
Therapeutic Advances in Advanced Basal Cell Carcinoma.

Samer Alkassis, Maya Shatta, Deborah J Wong

|Aug 29, 2023
A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma.

Glenn J Hanna, Myung-Ju Ahn, Jameel Muzaffar

Pageof 2

Frequent Collaborators

2 joint publications

Emrullah Yilmaz

2 joint publications

Nabil F Saba

2 joint publications

Kevin J Harrington

2 joint publications

Sung-Bae Kim